OpenAI 收购 Orchestra Bio，用智能体加速药物研发
OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI 收购 Orchestra Bio，要和自家 Rosalind 平台合并做药物研发智能体，Novo Nordisk 和 Moderna 已经在用它的方案了。
OpenAI 收购初创公司 Orchestra Bio，并计划将其并入旗下生命科学 AI 平台 Rosalind。合并后的目标是构建 AI 智能体，帮助制药团队协调药物开发流程，包括跟踪临床试验和发现问题。目前在美国研发一款新药平均需要 10 到 15 年。OpenAI 此前已与 Novo Nordisk 和 Moderna 在 AI 驱动的制药研究上展开合作。
OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research. The article OpenAI acquires Orchestra Bio to build AI agents that speed up drug development appeared first on The Decoder .
